French parliament OKs hep C drug rebate scheme
This article was originally published in Scrip
Executive Summary
The company rebate mechanism for the expensive new hepatitis C drugs including Gilead's Sovaldi will now be enshrined in French law, after the lower house of the parliament approved the social security financing bill (PLFSS) for 2015.
You may also be interested in...
Hepatitis C And PrEP Bring More Funding Headaches For NHS England
Drugs for hepatitis C and HIV prevention are causing funding problems for the NHS in England as court battles loom and innovation continues to bring more cost pressures.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.
'Don't Compromise The Pharma Innovation System,' Says Outgoing IFPMA Head Thomas Cueni
Thomas Cueni is stepping down after seven years at the helm of the International Federation of Pharmaceutical Manufacturers and Associations. In an interview with the Pink Sheet ahead of his retirement, he reflects on the proposed pandemic treaty, what still needs to be done to ensure equitable access to medicines, the importance of tackling AMR, moves towards regulatory reliance – and what his post-IFPMA life might look like.